CME

Faculty: Tracy Hicks, DNP, MBA

Faculty: Melissa Moody, MD

Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Tracy Hicks, DNP, MBA

Faculty: Melissa Moody, MD

Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Guest: Amy Spizuoco, DO, FAOCD

Practical Dermatology Editorial Board member Amy L. Spizuoco, DO, FAOCD, FAAD, describes the conversations she has with patients with atopic dermatitis who may be hesitant about remaining on a biologic treatment long-term.

Faculty: Jennifer Goldman, PharmD, CDCES, BC-ADM-FCCP

Faculty: Francisco Javier Ampudia-Blasco, MD, PhD

Continuous glucose monitoring (CGM) is still recommended for all individuals with diabetes, including those with type 2 diabetes (T2D). Despite this, its use in managing T2D has not been as widespread as expected. New evidence has recently highlighted the benefits of CGM for people with T2D. Join our panel of international experts as they explore these findings and discuss how to incorporate them into clinical practice.

Host: Chadwick R. Johr, MD

On-demand webcast with expert insights that untangle the common myths found in Sjögren’s disease by examining its pathophysiology, common signs/symptoms, and latest data on emerging, targeted therapies.

Faculty: Joseph Kim, MD, MPH, MBA, FACHE

Faculty: Samir Dalia, MD

Faculty: Christopher Jurief

This discussion, led by an expert in quality improvement (QI) implementation, will showcase the outcomes and experiences of clinicians participating in a QI initiative designed to improve the diagnosis, identification, and treatment of patients with HER2-expressing metastatic breast cancer (MBC). Panelists will share their successes and on-going challenges in the identification of patients with HER2-low or HER2-ultralow MBC and integration of HER2-directed ADCs among the healthcare team. Panelists will also highlight key findings, lessons learned, and improvements made as a result of the initiative. The discussion will focus on reporting and communication changes that promoted more visible and actionable information in support of interprofessional care coordination and treatment decision-making.

Faculty: Christian Mende, MD, FACP, FACN, FASN, FASH

Faculty: Deepak Bhatt, MD, MPH, MBA, FACC, FAHA

Recent data from 2024 and 2025 shed light on the prevalence of Cushing syndrome (hypercortisolism) among individuals with hard-to-control metabolic conditions. Now, 2026 brings even more up-to-date insights in this area. Join our expert faculty as they review the latest evidence and discuss its implications for clinical practice.

Faculty: Enriqueta Felip, MD

Faculty: Kristi Orbaugh, MSN, RNP, AOCN

This interview-style activity brings together a physician and nurse to explore the scientific rationale and clinical evidence behind subcutaneous (SC) immune checkpoint inhibitors (ICIs) in solid tumors. Through discussion of key clinical trials, they highlight pharmacokinetic equivalence, efficacy, and safety data compared with intravenous delivery. The conversation also offers practical insights for integrating SC ICIs into clinical workflows—including patient selection, administration techniques, and management of immune-related adverse events—while considering potential benefits for patient experience, nursing practice, and healthcare resource use.

Faculty: Mike Sharma, MD, MSc, FRCPC

Faculty: Ashkan Shoamanesh, MD

Faculty: Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA

Can an antithrombotic meaningfully reduce the risk of recurrent ischemic stroke without increasing major bleeding? Drs. Mike Sharma, Ashkan Shoamanesh, and Brian Mac Grory explore the science behind factor XIa inhibition and its potential to decouple thrombosis from hemostasis. The panel reviews pivotal OCEANIC-STROKE results presented at ISC 2026, highlighting a 26% relative risk reduction in ischemic stroke without an observed increase in ISTH major bleeding. They examine outcomes across stroke subtypes and place these results in context with other agents in development, such as milvexian and abelacimab. This conversation considers whether factor XI inhibition may alter long-standing assumptions about the tradeoff between efficacy and safety in secondary stroke prevention.

Faculty: Barbara O'Brien. MD

What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.